AstraZeneca achieved positive Phase 3 trial results for its drug Imfinzi in treating liver cancer. The drug is expected to become a 'super-blockbuster' and a major growth driver for the company. The treatment targets cases where tumors cannot be surgically removed, a category with historically limited options.
